TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?

With a global prevalence among adults over 18 years of age approaching 9%, Type 2 diabetes mellitus (T2DM) has reached pandemic proportions and represents a major unmet medical need. To date, no disease modifying treatment is available for T2DM patients. Accumulating evidence suggest that the sensor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gram, Dorte X., Fribo, Josefine, Nagy, Istvan, Gotfredsen, Carsten, Charrua, Ana, Hansen, John B., Hansen, Anker J., Szallasi, Arpad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722836/
https://www.ncbi.nlm.nih.gov/pubmed/31344877
http://dx.doi.org/10.3390/medsci7080082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722836/
https://www.ncbi.nlm.nih.gov/pubmed/31344877
http://dx.doi.org/10.3390/medsci7080082

Ejemplares similares